Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia

Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route

(2011) C. E. Dearden et al.   BLOOD

A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia

(2011) Peter Hillmen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium

(2011) W Wiktor-Jedrzejczak et al.   LEUKEMIA

Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study

(2010) Biju Krishnan et al.   BRITISH JOURNAL OF HAEMATOLOGY

A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas

(2010) Eckhart Weidmann et al.   LEUKEMIA & LYMPHOMA

Phase II Study of Alemtuzumab in Combination With Pentostatin in Patients With T-Cell Neoplasms

(2009) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group

(2009) Stephan Stilgenbauer et al.   JOURNAL OF CLINICAL ONCOLOGY